On Thursday, Stifel analysts maintained a Buy rating for Iovance Biotherapeutics (NASDAQ:IOVA), with a focus on the company's prospects for its Amtagvi product in late-line melanoma treatment. Stifel's analysts highlighted the lack of competition for Amtagvi and the potential for revenue growth supported by the expanding ATC footprint and improvements in out-of-specification rates.
Iovance Biotherapeutics' Proleukin product, while more challenging to assess, was also discussed by the analysts. They delved into the degree of stocking and forecasted steady-state levels, concluding that even modest growth in Amtagvi could meet revenue guidance and that Proleukin might become a more significant revenue contributor in the second half of 2025.
In addition to their outlook on Iovance, Stifel analysts expressed confidence in other biotech companies. They identified ACLX and IRON as having clinically de-risked assets poised for regulatory catalysts. Early-stage clinical catalysts from JSPR and IDYA were also seen positively, with JSPR showing remarkable momentum through a 214% return over the past year.
Currently trading at $21.85, JSPR maintains a strong balance sheet with more cash than debt, though InvestingPro analysis indicates high volatility with a beta of 2.19. RVMD was noted for having de-risking data in a large market with additional near-term value drivers in NSCLC and CRC. Furthermore, the analysts anticipate that PGEN will soon achieve approval for their first AdenoVerse drug in RRP.
The comprehensive analysis by Stifel not only underscores the potential of Iovance Biotherapeutics in the oncology space but also provides insights into the broader biotechnology sector, signaling optimism for several companies as they approach key regulatory and clinical milestones.
For deeper insights into JSPR and other biotech companies, InvestingPro subscribers can access detailed financial health scores, analyst consensus targets, and 8 additional ProTips that help evaluate investment potential in this dynamic sector.
In other recent news, Jasper Therapeutics has been making significant strides in its clinical trials. The company's SPOTLIGHT Phase 1b/2a study on briquilimab for treating Chronic Inducible Urticaria (CIndU) has shown promising initial results. The upcoming BEACON trial results, evaluating briquilimab's efficacy in treating Chronic Spontaneous Urticaria (CSU), are highly anticipated.
Analyst firms, including Oppenheimer, BMO Capital Markets, H.C. Wainwright, and BTIG, have maintained positive ratings on the company, with price targets ranging from $63 to $90. The company also received clearance from Health Canada to commence a Phase 1b/2a clinical trial for briquilimab as a potential treatment for asthma.
The U.S. Patent and Trademark Office registered a trademark for Jasper's proprietary Jasper c-Kit Mouse™ model, instrumental in the clinical development of briquilimab. These are the recent developments in Jasper Therapeutics' ongoing efforts to advance treatments for chronic diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.